227 related articles for article (PubMed ID: 33355247)
21. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
22. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of a dual sstr2 and integrin α
Liu B; Zhang Z; Wang H; Yao S
Bioorg Med Chem; 2019 Nov; 27(21):115094. PubMed ID: 31540828
[TBL] [Abstract][Full Text] [Related]
24. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
26. Comparative evaluation of
Xia Y; Zeng C; Zhao Y; Zhang X; Li Z; Chen Y
EJNMMI Res; 2020 Apr; 10(1):36. PubMed ID: 32297029
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
28. A Cyanine-Bridged Somatostatin Hybrid Probe for Multimodal SSTR2 Imaging in Vitro and in Vivo: Synthesis and Evaluation.
Heing-Becker I; Grötzinger C; Beindorff N; Prasad S; Erdmann S; Exner S; Haag R; Licha K
Chembiochem; 2021 Apr; 22(7):1307-1315. PubMed ID: 33238069
[TBL] [Abstract][Full Text] [Related]
29. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
31. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous Imaging of Ga-DOTA-TATE and Lu-DOTA-TATE in Murine Models of Neuroblastoma.
Zheng Y; Huh Y; Vetter K; Nasholm N; Gustafson C; Seo Y
IEEE Trans Radiat Plasma Med Sci; 2023 Jan; 7(1):75-82. PubMed ID: 37635919
[No Abstract] [Full Text] [Related]
33. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
34. Preliminary PET/CT Imaging with Somatostatin Analogs [
Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
[TBL] [Abstract][Full Text] [Related]
35. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.
Wadas TJ; Eiblmaier M; Zheleznyak A; Sherman CD; Ferdani R; Liang K; Achilefu S; Anderson CJ
J Nucl Med; 2008 Nov; 49(11):1819-27. PubMed ID: 18927338
[TBL] [Abstract][Full Text] [Related]
36. Comparison of receptor affinity of natSc-DOTA-TATE versus natGa-DOTA-TATE.
Koumarianou E; Pawlak D; Korsak A; Mikolajczak R
Nucl Med Rev Cent East Eur; 2011; 14(2):85-9. PubMed ID: 22219148
[TBL] [Abstract][Full Text] [Related]
37. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [
Plas P; Limana L; Carré D; Thiongane A; Raguin O; Mansi R; Meyer-Losic F; Lezmi S
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145306
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin receptor imaging with [
Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
[TBL] [Abstract][Full Text] [Related]
40. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
